Public Health · Research

Visceral Leishmaniasis (Kala-azar) reports

Coverage across 7 countries and regions. Each report follows the same 16 sections, with sources and data gaps named.

Get the full Visceral Leishmaniasis (Kala-azar) public health report

The full report covers burden, affected groups, risk factors, screening, treatment coverage, programmes, gaps and outlook, with a source and year for every figure.

Buy the full report Request free sample
Visceral Leishmaniasis (Kala-azar) reports by place
PlaceActive trialsReport
World9View report
Bangladesh0View report
Ethiopia3View report
India0View report
Kenya1View report
Nepal0View report
Sudan0View report

Public clinical research

9 active trials found worldwide on ClinicalTrials.gov.

See the public search

Latest public research

  1. "Combined novel ultra-diluted bioactive formulation enhances Sodium Stibogluconate efficacy via T cell-mediated cytokine modulation in experimental visceral leishmaniasis".Microbial pathogenesis, 2026
  2. A non-self polysaccharide rescues hosts from Leishmania-induced myelopoietic sabotage and promotes resistance to parasite re-infection.Cytokine, 2026
  3. Secondary Hemophagocytic Lymphohistiocytosis Triggered by Visceral Leishmaniasis in a Patient With Multiple Sclerosis Receiving Fingolimod Therapy: A Diagnostic Challenge.Cureus, 2026
  4. First Molecularly Confirmed Case of Leishmania infantum Visceral Leishmaniasis With Concomitant Atypical Cutaneous Disease in Panama in an HIV-Infected Patient.Open forum infectious diseases, 2026
  5. Widespread and diverse Wolbachia infections in sand flies from visceral leishmaniasis resurgence areas in China: potential candidates for sand fly control.Parasites & vectors, 2026

Public trial and paper counts come from ClinicalTrials.gov and PubMed. Acuitas market figures are not published on this page.